THE ABSTRACT SUBMISSION OF ISCOMS 2018 IS CLOSED!
GENERAL INFORMATION ABSTRACT SUBMISSION
The abstract submission is open from October 30th 2017 untill Februari 8th 2018.
The most important function of your abstract is to show that you have a valuable contribution to the congress and secondly, to lure the audience to your presentation. Abstracts will only be taken into account for the abstract selection procedure when they are written in English and do not exceed a maximum of 350 words. Furthermore, unfortunately, we cannot accept case-studies, reviews and literature studies (except for meta-analysis).
* Note: Preliminary results are allowed in your abstract.
Abstracts should contain the following subheadings:
There are no strict rules for writing an abstract. However, there are important guidelines that can help you improve your abstract, which can be found on our tips & tricks page.
To give you an idea of a well written abstract, please take a look at this abstract, written by former ISCOMS-participant Janet Vos:
Author: Janet Vos
Proven non-carriers in BRCA families have an earlier age of onset of breast cancer
Field of research
It is assumed that women who test negative for their family-specific BRCA1/2 mutation are not at increased risk anymore to develop breast or ovarian cancer. In the Netherlands, they are thus dismissed from intensive breast cancer screening and referred to the national breast cancer screening program starting at age 50. However, risk estimates for proven non-carriers in BRCA mutation families are inconsistent for breast cancer and are lacking for ovarian cancer. We aimed to assess the age-related risks for breast and ovarian cancer for proven non-carriers in these families.
Materials & Methods
A consecutive cohort study ascertained 464 proven non-carriers who had at least one first-degree relative with a pathogenic BRCA mutation. Kaplan-Meier analyses were used to estimate the age-related cancer risks, and we calculated standardized incidence ratios.
In the 464 non-carriers, 17 breast cancers were detected at a mean age of 47 years (95%CI 32-61) and two ovarian cancers were found at the age of 43 and 55 years. By age 50, the breast cancer risk among non-carriers was 6.4% (95%CI 2.9-9.8%) and the ovarian cancer risk was 0.4% (95%CI 0-1.3%). At this age the breast cancer risk in non-carriers was significantly higher than the risk in the general population. In particular, the number of breast cancers among proven non-carriers in BRCA1 families was higher than expected for the general population (SIR 40-49yr: BRCA1 4.5 (95%CI 1.8-9.2), BRCA2 2.1 (95%CI 0.3-7.6)). In the BRCA1 cohort, the mean number of breast cancer cases was higher in families in which non-carriers were diagnosed before age 50 (p=0.04).
The age at diagnosis of breast cancer in non-carriers in BRCA mutation families is younger than expected, yielding an increased risk in the fifth decade. This effect is most evident in BRCA1 families. If our results are confirmed by others, this could affect the advice given on breast cancer screening to proven non-carriers between age 40 and 50 in BRCA positive families.
BRCA, non-carrier, breast cancer, risk